Johnson & Johnson

JNJ

New York Stock Exchange. Currency in USD

163.36 -1.17 ( -0.71% )

Real time prices: September 30

Market Cap.
429.50B
Beta (5Y monthly)
0.61
Price/Earnings
16.47
EPS (TTM)
9.99
Forward Dividend
4.52 (2.74%)
Ex-Dividend Date
Aug 23, 2022
Volume
8.99M
1y Target Est.
186.89
Day's Range
163.32
-
165.74
52 Week's Range
155.72
-
186.69

Historical Summary

Performance
EPS growth
Share Buybacks

About Johnson & Johnson

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.jnj.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
2.63B
Employees
141700
Address
One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Latest news

Where to Invest $1,500 Right Now
Where to Invest $1,500 Right Now

Don't let a bear market environment stop you from investing in more great companies.
By The Motley Fool - 1 day ago

How To Aim For A Million Dollar Portfolio And Retire At 62
How To Aim For A Million Dollar Portfolio And Retire At 62

Click here to read more about several strategies and model portfolios that can help you...
By Seeking Alpha - 1 day ago

2 Perfect Index Funds to Buy in a Bear Market
2 Perfect Index Funds to Buy in a Bear Market

These Vanguard index funds have outperformed the broader stock market over the past year.
By The Motley Fool - 2 days ago

Why This Stock's 2.7% Dividend Yield Could Be the Safest on Wall Street
Why This Stock's 2.7% Dividend Yield Could Be the Safest on Wall Street

It's a Dividend King with a long reign still ahead.
By The Motley Fool - 2 days ago

Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say

On Wednesday, Immunovant Inc (NASDAQ: IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd's...
By Benzinga - 3 days ago

Is Johnson & Johnson a Buy?
Is Johnson & Johnson a Buy?

The healthcare giant has been a fairly stable investment this year, but does it belong...
By The Motley Fool - 3 days ago

Should Vanguard Value ETF (VTV) Be on Your Investing Radar?
Should Vanguard Value ETF (VTV) Be on Your Investing Radar?

Style Box ETF report for VTV
By Zacks Investment Research - 3 days ago

3 Reasons Why Cathie Wood Won't Touch This Warren Buffett Stock
3 Reasons Why Cathie Wood Won't Touch This Warren Buffett Stock

The factors keeping ARK Invest's boss away might actually be reasons to buy, depending on...
By The Motley Fool - 3 days ago